Compare Gilead Sciences, Inc. (GILD) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs S&P Global Inc — how do they compare? Gilead Sciences, Inc. trades at $147 (market cap $182.40B), while S&P Global Inc trades at $403.72 (market cap $118.72B). The key difference: Gilead Sciences, Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and S&P Global Inc for 123 Days on average.
| GILD | SPGI | |
|---|---|---|
Market Cap | $182.40B | $118.72B |
Volume | 4,469,821 | 1,647,917 |
Sector | Health | Financials |
52-Week High | $155.80 | $517.92 |
52-Week Low | $116.74 | $370.42 |
Typical Hold Time | 111 Days | 123 Days |
Enterprise Value | $205.46B | $130.21B |
Dividend Yield | 2.23% | 0.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
S&P Global (SPGI) trades at $395.18, down 0.24% on the day, with strong analyst support showing 85.7% buy ratings and a $509.50 consensus price target. The stock shows bearish technical signals but maintains robust fundamentals with 30.5% net margins and consistent revenue growth from $15.3B in 2025 to projected $16.1B in 2026. Recent developments include expansion into digital asset risk assessment and AI-driven growth initiatives.
The outlook remains positive given the company's dominant market position and financial strength, though technical weakness and high valuation multiples present near-term risks. Long-term growth drivers include AI integration and strategic acquisitions, while risks include market sensitivity to economic cycles and competitive pressures in financial services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
